These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31171755)

  • 1. [Complement-Mediated Mechanism and Complement Inhibitors in Guillain-Barré Syndrome].
    Kuwahara M; Kusunoki S
    Brain Nerve; 2019 Jun; 71(6):581-587. PubMed ID: 31171755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab in Acute Motor Axonal Neuropathy: An Ethical Application of an Off-Label Indication.
    Roy B; Nowak RJ
    J Clin Neuromuscul Dis; 2020 Sep; 22(1):63-64. PubMed ID: 32833730
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of eculizumab in Guillain-Barré syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial.
    Kuwabara S; Kusunoki S; Kuwahara M; Yamano Y; Nishida Y; Ishida H; Kasuya T; Kupperman E; Lin Q; Frick G; Misawa S
    J Peripher Nerv Syst; 2024 Sep; 29(3):339-349. PubMed ID: 38987228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.
    Davidson AI; Halstead SK; Goodfellow JA; Chavada G; Mallik A; Overell J; Lunn MP; McConnachie A; van Doorn P; Willison HJ
    J Peripher Nerv Syst; 2017 Mar; 22(1):4-12. PubMed ID: 27801990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New Complement Therapeutics in Complement-Related Diseases].
    Wakamiya N; Ohtani K; Hidaka Y; Inoue N
    Brain Nerve; 2019 Jun; 71(6):555-564. PubMed ID: 31171752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial.
    Misawa S; Kuwabara S; Sato Y; Yamaguchi N; Nagashima K; Katayama K; Sekiguchi Y; Iwai Y; Amino H; Suichi T; Yokota T; Nishida Y; Kanouchi T; Kohara N; Kawamoto M; Ishii J; Kuwahara M; Suzuki H; Hirata K; Kokubun N; Masuda R; Kaneko J; Yabe I; Sasaki H; Kaida KI; Takazaki H; Suzuki N; Suzuki S; Nodera H; Matsui N; Tsuji S; Koike H; Yamasaki R; Kusunoki S;
    Lancet Neurol; 2018 Jun; 17(6):519-529. PubMed ID: 29685815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
    Schols S; Nunn MA; Mackie I; Weston-Davies W; Nishimura JI; Kanakura Y; Blijlevens N; Muus P; Langemeijer S
    Br J Haematol; 2020 Jan; 188(2):334-337. PubMed ID: 31840801
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement C5 inhibition in patients with COVID-19 - a promising target?
    Peffault de Latour R; Bergeron A; Lengline E; Dupont T; Marchal A; Galicier L; de Castro N; Bondeelle L; Darmon M; Dupin C; Dumas G; Leguen P; Madelaine I; Chevret S; Molina JM; Azoulay E; Fremeaux-Bacchi V; Core Group
    Haematologica; 2020 Dec; 105(12):2847-2850. PubMed ID: 33256385
    [No Abstract]   [Full Text] [Related]  

  • 12. A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS).
    Yamaguchi N; Misawa S; Sato Y; Nagashima K; Katayama K; Sekiguchi Y; Iwai Y; Amino H; Suichi T; Yokota T; Nishida Y; Kohara N; Hirata K; Nishiyama K; Yabe I; Kaida KI; Suzuki N; Nodera H; Tsuji S; Koike H; Kira JI; Hanaoka H; Kusunoki S; Kuwabara S;
    JMIR Res Protoc; 2016 Nov; 5(4):e210. PubMed ID: 27821382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab in Pediatric Dense Deposit Disease.
    Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-complement therapy for glomerular diseases.
    Bomback AS
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future pharmacologic complement inhibitors.
    Risitano AM
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CompLement C5 Antibodies for decreasing brain injury after aneurysmal Subarachnoid Haemorrhage (CLASH): study protocol for a randomised controlled phase II clinical trial.
    Koopman I; Rinkel GJE; Vergouwen MDI;
    Trials; 2020 Nov; 21(1):969. PubMed ID: 33239044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
    Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
    Uzawa A; Kuwabara S
    Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
    Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.